FEBS Open Bio
 | |
| Discipline | Molecular Biosciences |
|---|---|
| Language | English |
| Edited by | Mary Purton |
| Publication details | |
| Publisher | |
Publication history | 2011 - present |
| Frequency | Monthly |
| Yes | |
| 2.101 (2015) | |
| Indexing | |
| ISSN |
2211-5463 |
| Links | |
FEBS Open Bio is a peer-reviewed scientific journal, for the rapid publication of research articles in molecular and cellular life sciences in both health and disease. The focus of the peer review process for FEBS Open Bio is on the technical soundness of manuscripts, leaving the assessment of their impact and biological significance to the scientific community. FEBS Open Bio publishes experimental findings, critical analysis, methodological and technical innovations, and hypotheses.
Submission of novel and innovative work is of course greatly encouraged, but papers describing solid science in developing fields or extending knowledge from one organism to another are also considered. FEBS Open Bio is also keen to receive papers reporting negative results, which are a valuable service to the community by avoiding the unnecessary duplication of effort and wasting of resources.
Articles originally submitted to other FEBS publications (FEBS Letters, The FEBS Journal and Molecular Oncology) can be transferred for consideration by FEBS Open Bio with their original reviewer reports, without the need to resubmit or reformat the manuscript.
The journal is published by FEBS Press and Wiley on behalf of the Federation of European Biochemical Societies (FEBS). Its editorial office is based in Cambridge, UK.
History
Journal publishing has been a core activity of FEBS since its conception in 1964. FEBS first launched the European Journal of Biochemistry (the original title of The FEBS Journal) in 1967, closely followed by FEBS Letters in 1968. These two journals rapidly grew into influential and respected forums for the dissemination of primary papers and reviews in biochemistry and molecular biology. In 2007, FEBS launched a new journal, Molecular Oncology, to serve the cancer community. Responding to the growing interest in, and demand for, open access publishing, FEBS extended its portfolio once again in 2011 when it launched FEBS Open Bio, in partnership with Elsevier. From 2017, all four journals will be published by FEBS Press, in partnership with Wiley.
Access
FEBS Open Bio is published online only, with free access of all content to all readers. Authors of accepted articles are charged a fee towards the costs of publication; a policy is in place to assist those who do not have funding for such charges.
Abstracting and Indexing
FEBS Open Bio is indexed in
- BIOSIS Previews (Thomson Reuters)
- EMBASE (Elsevier)
- PubMed (NLM)
- PubMed Central (NLM)
- SCOPUS (Elsevier)
- Science Citation Index Expanded (Thomson Reuters)
- Web of Science (Thomson Reuters)
According to the Journal Citation Reports FEBS Open Bio has a 2015 Impact Factor of 2.101, ranking it 197th out of 289 journals in the category "Biochemistry & Molecular Biology". FEBS Open Bio is a signatory of the San Francisco Declaration on Research Assessment (DORA), a set of recommendations that calls for the ‘need to assess research on its merits rather than on the basis of the Impact Factor of the journal in which the research is published’. Each article published in FEBS Open Bio displays citations data and a range of ‘alternative’ metrics that measure the impact of the article.
References
- Purton M (2014). “Making an impact: FEBS Open Bio celebrates its 3rd anniversary.” FEBS Journal, 281, 24, 5393–5394. DOI: 10.1111/febs.13144
- "Journals Ranked by Impact: Biochemistry & Molecular Biology". 2015 Journal Citation Reports. Web of Science (Sciences ed.). Thomson Reuters 2016.
- "The San Francisco Declaration on Research Assessment (DORA)", http://www.ascb.org/dora/